This trial is active, not recruiting.

Condition pulmonary embolism
Treatment treatment at home
Phase phase 4
Sponsor Carlos III Health Institute
Collaborator Spanish Society of Pneumology and Thoracic Surgery
Start date December 2004
End date August 2005
Trial identifier NCT00214929, PIO30192


The best management in selected patients of pulmonary Embolism (PE) should be at home. The efficacy and safety treatment´s at home versus at hospital should be similar and quality of life should be better. Our purpose is to demostrate that Low weight molecular heparin (LWMH) at home for PE is at least as effective and safe at home as at hospital

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment

Primary Outcomes

-Thromboembolic recurrences
time frame:
-Bleeding Complications
time frame:
time frame:

Secondary Outcomes

-Quality of life
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - The consecutive outpatients subjects diagnosed of PE at 10 different Spanish hospitals. - A score of 2 or under in our prediction rule (risk score for short-term) - Signed written Informed consent Exclusion Criteria: - A score over 2 in our prediction rule - Patients with a PE requiring thrombolysis or surgical thrombectomy - Patients with right ventricular dyskinesia in echocardiography at 48 hours from heparin therapy. (It is not necessary echocardiography for the model of discharge at 5 days) - Troponin level over 0,1 g/L - Patiens requiring oxygen therapy or under 93% in oxygen saturation level. - Patients requiring intravenous analgesic therapy - Patients with some medical or surgical conditions requiring to stay at hospital - Patients with advanced chronic cardiovascular diseases (dyspnea III-IV NYHA) - Patients with advanced chronic respiratory diseases (several COPD criteria of GOLD with FEV1< 50%) - Documented congenital or acquired bleeding tendency /disorder (s) - Documented current ulceration or angiodysplastic gastrointestinal disease - Hemorrhagic stroke or recent (< 3 months prior to randomization) brain, spinal, or ophthalmological surgery. - Recent surgery < 3 days - Pregnancy - Several Obesity (CMI over 30) - Patients could not complete the treatment at home. - Exclusion criteria related to study procedures - Life expectancy < 3 months

Additional Information

Official title Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism
Principal investigator Fernando Uresandi, MD
Description In order to carry out the Cooperative Investigation Plan for home treatment of pulmonary embolism, a network of multidisciplinary groups was built with the participation of 10 groups, distributed in 6 different regions and integrated within the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Those groups will share a database integrated in the Spanish Registry on Thromboembolic Disease (RIETE), which is a project already being carried out and in which many of the groups of the network already participate. The research project will be a study developed in two phases. In the first phase, predictive profiles for a favourable progression of the disease in patients with pulmonary embolism will be studied using the actual management of the disease with the current assistance model. In the second phase, a randomized study comparing the efficacy and safety of two models of home treatment ( discharge from hospital during the first 72 hours after the diagnosis of PE and discharge from hospital during the first 5 days) in patients previously selected, according to predefined criteria which were modified on the basis of the results of phase I versus the current assistance model will be developed The results will be measured in terms of efficacy, safety, economic burden, and quality of life in both models (at home and at hospital).
Trial information was received from ClinicalTrials.gov and was last updated in December 2005.
Information provided to ClinicalTrials.gov by Carlos III Health Institute.